STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[8-K/A] Kindly MD, Inc. Amends Material Event Report

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
8-K/A
Rhea-AI Filing Summary

Kindly MD, Inc. filed an amended Current Report (Form 8-K/A) that attaches exhibit-level disclosures for Nakamoto Holdings, Inc. The filing identifies the company's trading symbols as NAKA on The Nasdaq Stock Market LLC and NAKAW on the OTC Pink Market. It includes the consent of Wolf & Company, P.C., audited financial statements of Nakamoto as of April 30, 2025 and for the period from March 6, 2025 (inception) to April 30, 2025, unaudited financials as of June 30, 2025, unaudited pro forma condensed combined financial statements reflecting the acquisition of Nakamoto, supplemental risk factors, and management discussion and analysis for the stated periods. The filing is executed by CEO David Bailey.

Positive
  • Audited financial statements of Nakamoto Holdings, Inc. as of April 30, 2025 are included, improving reliability of historical financial information
  • Unaudited interim financials as of June 30, 2025 provide recent operating data
  • Unaudited pro forma condensed combined financial statements explicitly give effect to the acquisition of Nakamoto, enabling assessment of the combined entity
  • Auditor consent from Wolf & Company, P.C. is provided, supporting filing completeness
Negative
  • Supplemental risk factors are included, indicating additional risks that may affect the combined business
  • Filing text is limited to exhibit descriptions and does not disclose detailed financial amounts or metrics within the body of this excerpt

Insights

TL;DR: The amendment supplies audited and pro forma financials tied to the Nakamoto acquisition, improving transparency for investors.

The filing provides foundational financial disclosures: audited statements through April 30, 2025, unaudited interim results to June 30, 2025, and pro forma condensed combined statements giving effect to Kindly MD's acquisition of Nakamoto Holdings, Inc. These exhibits are material because they allow investors to assess historical results and the combined entity's immediate financial presentation. Inclusion of the auditor consent is standard but important for filing completeness. Supplemental risk factors and MD&A additions increase disclosure on potential issues and business context.

TL;DR: The pro forma statements explicitly reflect the acquisition, enabling assessment of post-transaction financial position and operations.

The amended report includes unaudited pro forma condensed combined financial statements that state they give effect to Kindly MD's acquisition of Nakamoto Holdings, Inc., including a pro forma balance sheet as of June 30, 2025 and pro forma statements of operations for relevant periods. For transaction analysis, these exhibits are essential to evaluate immediately combined scale and near-term results. Supplemental MD&A and risk factor exhibits further clarify the deal's implications and disclosure completeness.

true UT 0001946573 0001946573 2025-08-11 2025-08-11 0001946573 NAKA:CommonStockParValue0.001Member 2025-08-11 2025-08-11 0001946573 NAKA:TradeableWarrantsToPurchaseSharesOfCommonStockParValue0.001PerShareMember 2025-08-11 2025-08-11 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.

 

FORM 8-K/A

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): August 11, 2025

 

Kindly MD, Inc.

(Exact name of registrant as specified in its charter)

 

001-42103   84-3829824
(Commission File Number)   (IRS Employer Identification Number)
     
5097 South 900 East, Suite 100, Salt Lake City, UT   84117
(Address of Principal Executive Offices)   (Zip Code)

 

(385) 388-8220

(Registrant’s telephone number, including area code)

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class   Trading Symbol(s)   Name of Each Exchange on Which Registered
Common Stock, par value $0.001   NAKA   The Nasdaq Stock Market LLC
Tradeable Warrants to purchase shares of Common Stock, par value $0.001 per share   NAKAW   OTC Pink Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

 

 

 

Explanatory Note

 

On August 15, 2025, Kindly MD, Inc. (the “Company”) filed with the U.S. Securities and Exchange Commission a Current Report on Form 8-K (the “Initial Form 8-K”) to report the consummation of the transactions contemplated by that certain Agreement and Plan of Merger (the “Merger Agreement”) by and among the Company, Kindly Holdco Corp, a Delaware corporation and a direct, and wholly owned subsidiary of the Company (“Merger Sub”), Nakamoto Holdings Inc., a Delaware Corporation (“Nakamoto”) and Wade Rivers, LLC, a Wyoming limited liability company (“Wade Rivers”) and related issuance of common stock and pre-funded warrants (the “PIPE Transaction”) and issuance of convertible debentures (the “Debt Transaction”). Pursuant to the Merger Agreement, among other things, Merger Sub merged with and into Nakamoto, with Nakamoto surviving as a wholly owned subsidiary of the company (such transaction, the “Merger”). The Merger closed on August 14, 2025 (the “Closing Date”).

The Company is filing this Amendment No. 1 on Form 8-K/A to the Initial Form 8-K (this “Amendment) for the purpose of amending the Initial Form 8-K to provide certain historical financial information of Nakamoto and unaudited pro forma condensed combined financial data of the Company in accordance with Items 9.01(a) and 9.01(b) of Form 8-K, respectively, and the incorporation of disclosure regarding supplemental risk factors, Management Discussion and Analysis and Information on Nakamoto disclosures in Item 8.01 on of Form 8-K. No other changes to the Initial Form 8-K are being made hereby. This Amendment should be read in conjunction with the Initial Form 8-K, which provides a more complete description of the Merger and PIPE Transaction and the Current Report on Form 8-K filed with the SEC on August 15, 2025, regarding the Debt Transaction.

 

1

 

 

Item 8.01 Other Events.

 

The Company is filing this amendment to supplement its prior disclosures in connection with the Merger, the PIPE Financings, and related transactions described in the Initial Form 8-K. Specifically, the Company is providing additional risk factors addressing cybersecurity and data privacy matters and risks related to the bitcoin treasury strategy (the “Supplemental Risk Factors”), as well as updated Management’s Discussion and Analysis and Information about Nakamoto disclosures relevant to its business. These updates are intended to supplement and update the disclosures previously included in the Company’s public filings, including those under the headings “Risk Factors,” “Management’s Discussion and Analysis,” and “Information About Nakamoto” in the Company’s Definitive Information Statement (filed with the SEC on July 22, 2025), Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 (filed with the SEC on August 5, 2025), and the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 (filed with the SEC on March 28, 2025, as amended).

 

The supplemental risk factors related to the bitcoin treasury strategy, cybersecurity and data privacy are filed herewith as Exhibit 99.3 to this Form 8-K/A and are incorporated herein by reference. Management’s Discussion and Analysis and Information About Nakamoto disclosures are filed herewith as Exhibits 99.5, 99.6 and 99.7 to this Form 8-K/A and are also incorporated herein by reference.

 

Item 9.01 Financial Statements and Exhibits.

 

(a) Financial Statements of Business Acquired.

 

The audited financial statements (and notes thereto) of Nakamoto Holdings, Inc. as of April 30, 2025, and for the period from March 6, 2025 (inception) to April 30, 2025, are filed as Exhibit 99.1 to this Form 8-K/A.

 

The unaudited financial statements (and notes thereto) of Nakamoto Holdings, Inc. as of June 30, 2025, and for the period from March 6, 2025 (inception) to June 30, 2025, are filed as Exhibit 99.2 to this Form 8-K/A.

 

(b) Pro Forma Financial Information.

 

The unaudited pro forma condensed combined financial information reflecting the acquisition of Nakamoto Holdings, Inc., including the unaudited pro forma condensed combined balance sheet as of June 30, 2025 and the unaudited pro forma condensed combined statement of operations for the sixth months ended June 30, 2025 and for the year ended December 31, 2024, are filed as Exhibit 99.3 to this Form 8-K/A.

 

(d) Exhibits.

 

Exhibit No.   Description of Exhibit
23.1   Consent of Wolf & Company, P.C.
99.1   Audited Financial Statements of Nakamoto Holdings, Inc. as of April 30, 2025, and for the period from March 6, 2025 (inception) to April 30, 2025 (incorporated by reference to the definitive information statement filed by the Company on July 22, 2025).
99.2   Unaudited Financial Statements of Nakamoto Holdings, Inc. as of June 30, 2025, and for the period from March 6, 2025 (inception) to June 30, 2025.
99.3   Unaudited pro forma condensed combined financial statements of Kindly MD, Inc. giving effect to the acquisition of Nakamoto Holdings, Inc., including the unaudited pro forma condensed combined balanced sheet as of June 30, 2025, and the unaudited pro forma combined statement of operations for the three-months ended June 30, 2025, and the year ended December 31, 2024.
99.4   Supplemental Risk Factors
99.5   Management Discussion and Analysis for the period from March 6, 2025 (inception) to June 30, 2025
99.6   Information About Nakamoto
99.7   Management Discussion and Analysis for the period from March 6, 2025 (inception) to April 30, 2025
104   The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.

 

2

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunder duly authorized.

 

  KINDLY MD, INC.
     
Dated: August 25, 2025 By: /s/ David Bailey
    David Bailey
    Chief Executive Officer

 

 

3

 

 

FAQ

What financial statements are included in Kindly MD's 8-K/A for NAKA?

Audited financial statements of Nakamoto as of April 30, 2025, unaudited financial statements as of June 30, 2025, and unaudited pro forma condensed combined financial statements giving effect to the acquisition.

Does the filing confirm an acquisition related to Nakamoto Holdings, Inc.?

Yes. The filing states the unaudited pro forma condensed combined financial statements give effect to the acquisition of Nakamoto Holdings, Inc.

Which auditor provided consent in the 8-K/A?

Wolf & Company, P.C. provided the consent included as an exhibit in the filing.

What trading symbols are listed for Kindly MD and its warrants?

NAKA for Common Stock on The Nasdaq Stock Market LLC and NAKAW for tradeable warrants on the OTC Pink Market.

Who signed the amended report?

David Bailey, Chief Executive Officer of Kindly MD, Inc., executed the filing.
Kindly Md, Inc.

NASDAQ:NAKA

NAKA Rankings

NAKA Latest News

NAKA Latest SEC Filings

NAKA Stock Data

243.41M
413.13M
5.96%
0.22%
0.39%
Medical Care Facilities
Services-health Services
Link
United States
SALT LAKE CITY